News related to the Enterprise, its Stakeholders, and HIV Vaccine Research

Anthony Fauci on The Colbert Report - April 1, 2011

Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, discusses why HIV is still a problem during his interview on The Colbert Report.  Watch the interview here.

Funding Opportunity: The Canadian HIV Technology Development Program - April 1, 2011


On April 01, 2011, small and medium enterprises (SMEs) in Canada were invited to submit project proposals for the new Canadian HIV Technology Development (CHTD) program.  The CHTD falls under the Translating Basic Science into Clinical Trials program area of the Canadian HIV Vaccine Initiative (CHVI), a collaboration between the Government of Canada and the Bill & Melinda Gates Foundation. 

Funding Opportunity: Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) - March 31, 2011

The National Institute of Allergy and Infectious Diseases (NIAID) invites applications to establish a Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID). CHAVI-ID will support a coordinated, multidisciplinary team of researchers focused on multi-pronged approaches to accelerate HIV vaccine development by addressing key immunological roadblocks to the discovery and development of a safe and effective HIV vaccine.

A ‘dance’ before a trial begins - March 31, 2011

The blog Science Speaks: HIV &TB News published a profile of Col. Nelson L. Michael, who is in charge of the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research. Michael has visited Mozambique several times to discuss with Mozambique’s National Institute of Health about a potential HIV vaccine clinical trial to begin in 2014. It is not yet known what type of trial will be conducted, according to Science Speaks. “Mozambique already has a core of strong physician-researchers. We think by 2014, we can conceive a large-scale efficacy trial.

Is an HIV vaccine imminent? Scientists to begin trialling breakthrough drug 'next year' - March 31, 2011

An HIV vaccine that could outwit the deadly virus could undergo human trials in as little as a year's time, scientists say. Read the full article here.

The Sixth EDCTP Forum Sponsor - March 25, 2011

The Sixth EDCTP Forum is now inviting interested organizations to sponsor the event. The Forum is one of the major conferences in Africa related to HIV/AIDS, malaria and tuberculosis. For more information, click here.

HIV vaccine design program launched in India - March 3, 2011

The Translational Health Sciences and Technology Institute (THSTI), an autonomous institute of the Government’s Department of Biotechnology, and the International AIDS Vaccine Initiative (IAVI) has jointly announced an agreement to operate and fund an HIV vaccine design program in India. Read the full article here.

CROI — Day 2: Selected highlights of NIH-supported research - March 2, 2011

Jerome H. Kim, M.D., of the U.S. Military HIV Research Program in Rockville, Md., discussed the search for antibodies that could help explain why some participants in the Thai-based RV144 HIV vaccine trial were protected against HIV. Read the full article here.

IAVI Releases January - February 2011 Report - March 1, 2011

See below for the full report.

IAVI and Partners Initiate AIDS Vaccine Trial in Africa - February 28, 2011

IAVI announced the start of a multi-center Phase I trial in Africa to evaluate the safety and immunogenicity of a preventive AIDS vaccine candidate made up of two components. The trial, named B002, is the first to test these components used in combination, with the aim of producing broader and stronger immune responses than can be achieved with either component alone. One component of the vaccine combination is based on a recombinant protein. The other is constructed using a virus other than HIV as a vector to transport man-made versions of HIV genes into the body.

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account